智擎生技製藥股份有限公司 - Section 3
3/5
★
基於 7 評論
Contact 智擎生技製藥股份有限公司
| 地址 ： | 10491, Taiwan, Taipei City, Zhongshan District, Section 3, Minsheng E Rd, 10號智擎生技製藥股份有限公司11樓 |
| 電話 ： | 📞 +8888 |
| 分類： |
製藥公司
,
|
| 城市 ： | Minsheng E Rd |
|
C
|
C. S on Google
★ ★ ★ ★ ★ |
|
吳
|
吳彼得 on Google
★ ★ ★ ★ ★ 人文薈萃，，，
 A gathering of humanities,,,
|
|
羅
|
羅羅三 on Google
★ ★ ★ ★ ★ 2022 加油
2022 Come on
|
|
L
|
LINDY L on Google
★ ★ ★ ★ ★ 從來沒有買過這麼爛的股票 300元到現在跌了80%每次都發沒有用的聲明，股價跟公司營運絕對有正相關！！！不要只會每次發沒用聲明！！
難怪PTT都說，買生技股要在STOCK版公告，要投資人小心避免買這樣爛的股票，大盤在萬點也沒彈，誇張！
I have never bought such a bad stock. The price of 300 yuan has dropped by 80%. It is useless every time. The stock price is absolutely positively related to the company's operation! ! ! Don't just make a statement every time! !
It is no wonder that PTT said that buying biotech stocks should be announced in the STOCK version, and investors should be careful to avoid buying such bad stocks. The market is not playing at 10,000 points, exaggeration!
|
|
K
|
K CC on Google
★ ★ ★ ★ ★ 被某公司亂攪和，股價跌的跟屎一樣!!!
真棒 股價回春到七年前的低點
Stir-up by a company, the stock price fell like the same as!!!
Awesome stock price revived to a low of seven years ago
|
|
L
|
Lee Kyson on Google
★ ★ ★ ★ ★ 胰臟癌 癌中之王 智擎有這個實力 就要鼓勵加油
Pancreatic cancer, the king of cancer, Zhiqing has this strength, we must encourage it
|
|
R
|
Richard Haung on Google
★ ★ ★ ★ ★ 集團領導者取得了經營權卻不懂經營,經營績效極度不獲市場認同導致股價跌跌不休,是一間有好體質卻沒有好領導者可惜的好公司.
近期公司主力產品安能得成功獲准中國藥證,及下半年小細胞二線三期解盲、2023上半年胰腺癌一線三期解盲,為公司帶來長久以來股價巨大的轉機,可以關注後續發展.
去除掉大股東因素,因公司未來轉機調高評等.
The leader of the group has obtained the right to operate but does not know how to operate, and the operating performance is extremely unrecognized by the market, causing the stock price to fall endlessly. It is a good company with good physique but no good leader.
Recently, the company's main product, Annergy, was successfully approved for Chinese medicine, and the second-line and third-phase blindness of small cells in the second half of the year and the first-line and third-phase blindness of pancreatic cancer in the first half of 2023 have brought the company a huge turnaround in the stock price for a long time. You can pay attention to the follow-up. develop.
Remove the major shareholder factor, due to the company's future turnaround, the rating will be raised.
|
Write some of your reviews for the company 智擎生技製藥股份有限公司
您的評論將非常有助於其他客戶查找和評估信息
Recommend a place for you
